RARE earnings analysis
What we found in RARE's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Ultragenyx delivered a strong Q2 rebound, with $214.0 million of revenue rising 57.4% sequentially and 28.9% year over year, while the $0.90 EPS loss narrowed substantially from both comparison periods and beat consensus. The improving earnings trend is tempered by a $301 million decline in cash and investments to $436 million, continued near-term operating losses, and reliance on KKC royalties, which made up 48% of quarterly revenue. Management did not provide numerical guidance in the supplied filing text but continues to target profitability in 2027.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue rebounded strongly
- Q2 revenue was $214.0 million, up $78.0 million, or 57.4%, from $136.0 million in Q1 2026 and up $48.0 million, or 28.9%, from $166.0 million in Q2 2025. Revenue also exceeded the $182.5 million consensus estimate by $31.5 million.
- EPS loss narrowed materially
- Diluted EPS was a loss of $0.90, improving from a $1.84 loss in Q1 2026 and a $1.17 loss in Q2 2025. The result was $0.26 per share better than the estimated $1.16 loss.
- Profitability target remains 2027
- Management states it currently expects to achieve profitability in 2027, despite continuing to expect operating losses in the near term.
- Dojolvi patent protection extended
- The company obtained U.S. Patent No. 12,551,461 for Dojolvi in February 2026; the patent is expected to expire in 2034. This adds protection beyond the existing 2029-expiring '748 patent.
- Restructuring cash actions completed
- Management completed expected cash payments for its February 2026 restructuring during the six months ended June 30, 2026. The plan included a 10% workforce reduction of approximately 130 employees.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Liquidity declined sharply
- Cash, cash equivalents and marketable securities fell to $436 million at June 30, 2026 from $737 million at December 31, 2025, a $301 million, or 40.8%, reduction. Management says it may need additional capital to commercialize products and fund development.
- Profitability execution remains uncertain
- The company continues to expect operating losses in the near term and says that achieving profitability in 2027 depends on assumptions that may materially differ from actual results.
- High dependence on KKC royalties
- A new risk disclosure highlights concentration in Crysvita economics: KKC royalty revenue represented 48% of total revenue in Q2 2026 and 43% in the first six months. KKC has no obligation to use diligent efforts to commercialize Crysvita in its territories.
- Dojolvi generic challenges expanded
- Generic risk intensified with a July 2026 Hatch-Waxman suit against Sun Pharma over Dojolvi. The product's orphan-drug exclusivity for LC-FAOD expires June 30, 2027, while the asserted '748 and '461 patents expire in 2029 and 2034, respectively.
- UX111 manufacturing remediation risk
- Regulatory/manufacturing risk remains material: the FDA issued a complete response letter for UX111 in July 2025 citing information and improvements tied to inspections of the company facility and a third-party manufacturer.
- UX143 litigation follows trial failure
- Newly disclosed stockholder litigation adds legal exposure: a February 2026 putative securities class action and March 2026 derivative complaint seek unspecified damages related to the UX143 Orbit and Cosmic trials, which missed primary endpoints in December 2025.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.9
What they said about what is next.
No quantitative revenue or EPS outlook was included in the provided 10-Q text. Management states that it currently expects to achieve profitability in 2027.
The filing reads better than the one before it.
What came before.
- 10-Q · May 5, 2026
- Ultragenyx Pharmaceuticals reported disappointing Q1 2026 results, with revenue of $136 million, significantly below the forecasted $158.98 million. The company also reported a loss per share of $1.84, missing the…
- 10-K · February 18, 2026
- Ultragenyx positions itself as a rare/ultra-rare disease specialist focused on time- and cost-efficient development, in‑licensing assets and retaining global commercialization rights. FY2025 revenue totaled $672.0M (Q4…
- 10-Q · November 5, 2025
- Ultragenyx reported Q3 revenue of $159.9M, up 14.7% year-over-year but down vs. the prior quarter; gross margin compressed to 82.5% and operating losses widened, driving GAAP diluted EPS of -$1.81. Cash and cash…
- 10-Q · May 7, 2025
- Ultragenyx reported Q1 2025 revenue of $139.3M and product sales of $91.5M, up year‑over‑year, while net loss narrowed to $151.1M (EPS -$1.57). Operating loss improved versus the prior-year quarter but the company…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing RARE makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever